Trial · NCT05174416
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient | Mavacamten | -51.05 | Standard Deviation 6.150 | mmHg | |
| Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient | Placebo | 19.23 | Standard Deviation 8.535 | mmHg | |
| Change From Baseline to Week 30 in Resting LVOT Peak Gradient | Mavacamten | -49.04 | Standard Deviation 4.637 | mmHg | |
| Change From Baseline to Week 30 in Resting LVOT Peak Gradient | Placebo | 5.95 | Standard Deviation 6.311 | mmHg | |
| Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 30 mmHg at Week 30 | Mavacamten | 26 | Participants | ||
| Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 30 mmHg at Week 30 | Placebo | 1 | Participants | ||
| Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 50 mmHg at Week 30. | Mavacamten | 32 | Participants | ||
| Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 50 mmHg at Week 30. | Placebo | 2 | Participants | ||
| Proportion of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Classification From Baseline to Week 30 | Mavacamten | 32 | Participants | ||
| Proportion of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Classification From Baseline to Week 30 | Placebo | 4 | Participants | ||
| Change From Baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) | Mavacamten | 4.99 | Standard Deviation 2.063 | score on a scale | |
| Change From Baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) | Placebo | -5.25 | Standard Deviation 2.750 | score on a scale | |
| Change From Baseline to Week 30 in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) | Mavacamten | 0.182 | Standard Deviation 0.1743 | ng/L | |
| Change From Baseline to Week 30 in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) | Placebo | 0.932 | Standard Deviation 0.5133 | ng/L | |
| Change From Baseline to Week 30 in Cardiac Troponin | Mavacamten | 0.419 | Standard Deviation 0.1983 | ng/L | |
| Change From Baseline to Week 30 in Cardiac Troponin | Placebo | 1.236 | Standard Deviation 0.6528 | ng/L | |
| Change From Baseline to Week 30 in Left Ventricular (LV) Mass Index | Mavacamten | -26.365 | Standard Deviation 21.0565 | g/m^2 | |
| Change From Baseline to Week 30 in Left Ventricular (LV) Mass Index | Placebo | 4.434 | Standard Deviation 14.4226 | g/m^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05174416/results